ClinicalTrials.gg
TerminatedNCT05014087DIGIT-AlcHepUpdated Sep 29, 2026Results posted

Digoxin In Treatment of Alcohol Associated Hepatitis

A Phase 2 interventional study of Intravenous digoxin in Acute Alcoholic Hepatitis, Chemical and Drug Induced Liver Injury and Alcohol-Induced Disorders, sponsored by Yale University. Terminated at 1 site in United States. Open to participants aged 21 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Yale University · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Slow accrual
Updated Sep 29, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
21 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Chemical and Drug Induced Liver Injury with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Chemical and Drug Induced Liver Injury · United States.

Enrollment
8th of 10
23 · median 30
Started
2021
the only one that year
Phase 2
4 of 13
1 open now
Registered
9th of 13
by date

Among the 13 studies in Chemical and Drug Induced Liver Injury with a site in United States, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2021, is one of 4 in phase 2, and was the 9th registered.

Chemical and Drug Induced Liver Injury

81 studies on the registry are indexed under Chemical and Drug Induced Liver Injury; 21 are open to participants now.

Browse Chemical and Drug Induced Liver Injury studies →

Open to participants now

2 of the 13 studies in Chemical and Drug Induced Liver Injury with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Chemical and Drug Induced Liver Injury studies recruiting now, 7 (58%) set no upper age limit and 3 (25%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 21 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Chemical and Drug Induced Liver Injury with a site in United States, or all of them as a file.
02

Study summary

Prospective, single center, open label, randomized controlled trial to explore whether digoxin treatment affects cytokine levels as biomarkers of inflammation in patients with acute alcohol associated hepatitis, digoxin administration and dose adjustment.

The study intervention will be intravenous digoxin (renal-based dosing for maximum of 28 days) versus no digoxin in an open-label 1:1 randomized allocation of patients with severe acute alcohol associated hepatitis.

Read the detailed description

Severe alcohol associated hepatitis is a condition of acute on chronic immune liver dysfunction that is associated with high mortality, necessitating a search for drugs that may prove safe and efficacious in treating this disease. Pre-clinical studies suggest that digoxin, which is currently used for treating cardiac conditions, is also effective in improving alcohol-associated liver injury. To date, there have been no clinical studies of digoxin use in patients with alcohol associated hepatitis.

The primary objective of this randomized control study of digoxin versus no digoxin in patients with severe alcohol associated hepatitis is to explore whether digoxin treatment affects cytokine levels as biomarkers of inflammation in patients hospitalized with severe alcohol associated hepatitis.

03

Conditions studied

  • Acute Alcoholic Hepatitis
  • Chemical and Drug Induced Liver Injury
  • Alcohol-Induced Disorders
  • Steatohepatitis Caused by Ingestible Alcohol

Keywords

  • Acute alcoholic hepatitis
  • Liver injury
  • Liver inflammation
  • Liver disease
  • Digoxin
04

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. Diagnosis of alcohol associated hepatitis based on clinical criteria or histologic evidence

  1. Clinical criteria:

    • Onset of jaundice ( >3 mg/dL) within the prior 8 weeks
    • Regular alcohol use > 6 months, with intake of > 40 g/day (>280 g/week) for women; and > 60 g/day (>420 g/week) for men
    • > 50 IU/l
    • AST: ALT > 1.5 and both values \< 400 IU/l
  2. Histological evidence of alcohol associated hepatitis*

    2. MDF >32 or MELD ≥ 20 to ≤ 35 on Day 0 of the trial

    3. Age between 21 and 70 years, inclusive

    * In patients with possible alcohol associated hepatitis with confounding factors such as possible ischemic hepatitis, possible DILI, uncertain history of alcohol use, or atypical/abnormal laboratory tests (e.g., AST \< 50 IU/IU/L or > 400 IU/IU/L, AST/ALT ratio \< 1.5), antinuclearantibody > 1:160 or SMA > 1:80, standard of care liver may be performed as per discretion of the primary attending physician to confirm alcohol associated hepatitis and exclude competing etiologies. The decision to perform liver biopsy will be made by the primary team and will occur regardless of the study. As per current SOC, a liver biopsy may be obtained to confirm suspected alcohol-associated hepatitis and to rule out other potential etiologies of liver disease.

    If a liver biopsy is performed for clinically indicated reasons, we will store liver tissue that is left over after the portion needed for the primary indication has been identified.

Exclusion criteria

Exclusion Criteria:

  1. - Currently pregnant or breastfeeding
  2. - Inability of patient, legally authorized representative or next-of-kin to provide
  3. - Allergy or intolerance to digoxin
  4. - Clinically active C. diff infection
  5. - Positive test for COVID-19 within 14 days prior to the screening visit
  6. - Acute hepatitis E, Cytomegalovirus, Epstein Barr Virus, Herpes Simplex Virus

7- History of other liver diseases including (positive HBsAg or HBV DNA), hepatitis 8-C (positive ), hepatitis, Wilson disease, genetic hemochromatosis, alpha1-antitrypsin deficiency.

8-Diagnosis of Drug Induced Liver Injury (DILI), or other etiologies seen on liver imaging.

9 - History of infection (positive HIV RNA or on treatment for HIV infection)

10 - Current diagnosis of cancer

11- Renal failure defined by \<30 mL/min

12 - ascites, defined as having more than 4 paracenteses in the preceding 8 weeks despite diuretic therapy

13 - Prior exposure to experimental therapies or other clinical trial in last 3 months

14 - Current acute or chronic pancreatitis

15 - Active gastrointestinal bleeding unless resolved for >48 hours

16 - Experiencing withdrawal seizures or considered at high risk for alcohol withdrawal seizures or delirium tremens

17 - Heart rate less than 60 bpm at screening visit or at baseline

18 - Current diagnosis of atrial fibrillation

19 - Cardiomyopathy

20 - Heart failure

21 - Severe aortic valve disease

22 - Presence of Accessory arterio-ventricular pathway (eg Wolf-Parkinson-White syndrome)

23 - Complete heart block or second degree arterio-ventricular block without pacemaker or implantable cardiac device

24 - Any of the following within the previous 6 months: myocardial infarction, percutaneous intervention, pacemaker/implantable cardiac device implantation, cardiac surgery or stroke

25 - Current use of the following medications:

  • Antiarrhythmic (amiodarone, dofetilide, sotalol, dronedarone)
  • Parathyroid hormone analog (teriparatide)
  • Thyroid supplement (thyroid, levothyroxine sodium)
  • Sympathomimetics or ionotropic drugs (epinephrine, norepinephrine, dopamine, dobutamine, milrinone)
  • Neuromuscular blocking agents (succinylcholine)
  • Calcium supplement
  • Ivabradine
  • Disulfiram
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Arm A: Digoxin

    In the digoxin arm, the intervention to be administered will be intravenous digoxin dosed by weight and by renal function using an adaption of the established FDA nomogram. Participants randomized to digoxin will receive an intravenous digoxin loading dose administered in 3 doses over 24 hours starting on Day 1. Digoxin levels will be monitored daily throughout the participant's hospital stay, to a maximum of 28 days. Digoxin will be discontinued at the time discharge if before 28 days.

    Drug: Intravenous digoxin

  • No intervention
    Arm B: No Digoxin

    In the no digoxin arm, no study drug or placebo will be administered.

Interventions

  • DrugDigoxinStudies of DigoxinDigoxin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Loading dose: the total loading dose of digoxin will be determined using the Loading nomogram. The FDA-recommended total IV digoxin loading dose range is 8 to 12 mcg/kg. The lowest recommended dose of 8 mcg/kg was used in constructing the digoxin Loading nomogram that will be used in this trial. Maintenance dose: the maintenance dose will be started approximately 24 hours after initiation of digoxin loading. The post-loading digoxin trough will be reviewed prior to starting maintenance dosing. Subjects on P-gp inhibitors or spironolactone, will have an additional digoxin level performed 12-hours after any dose adjustment. Once digoxin levels are stable, 24-hour blood draws will be performed.

    Also known as: Lanoxin

06

What researchers measure

Primary outcomes

  1. Change in Biomarkers of Inflammation

    Change in IL-6, IL-10 and TNF-alpha levels (pg/ml) at day 3 in participants with acute alcohol associated hepatitis treated with digoxin vs no digoxin.

    Time frame: Day 3

Secondary outcomes

  1. Practicality of Daily Digoxin Measurements

    Practicality of daily digoxin measurements is recorded at the participant level as the proportion of timepoints where serum digoxin levels are checked within the pre-specified time window. It is summarized and reported as the mean and standard deviation of the proportion of eligible timepoints.

    Time frame: From Day 2 to Day 28 or until discharge, whichever sooner

  2. Feasibility of Digoxin Dosing in a Timely Manner.

    Feasibility of digoxin dosing is recorded at the participant level as the proportion of eligible timepoints where the scheduled digoxin dose was given. It is summarized and reported as the mean and standard deviation of the proportion of scheduled timepoints.

    Time frame: From Day 1 to Day 28 or until discharge, whichever sooner

  3. Feasibility of Digoxin Dose Adjustments in Renal Insufficiency.

    Feasibility of digoxin dose adjustments in renal insufficiency is recorded at the participant level as the proportion of timepoints where necessary dose adjustments were made appropriately in response to digoxin levels. Renal insufficiency was defined as a creatinine rise ≥ 0.3 mg/dL over 48 hours or ≥ 20% from baseline or requiring renal replacement therapy. It is reported as the mean and standard deviation of the proportion of timepoints.

    Time frame: From Day 0 to Day 28 or until discharge, whichever sooner

  4. Mortality at 7, 14, 28, 90 Days. All Cause Mortality of Patients Enrolled in the Trial.

    The mortality rates at different time points

    Time frame: Day 7, Day 14, Day 28, and Day 90

  5. Development of Arrhythmia

    It refers to any type of arrhythmia which represents a change from baseline. It is reported as the proportion of individuals who developed an arrhythmia.

    Time frame: From Day 0 to Day 28 or until discharge, whichever sooner

  6. Recruitment

    Ability to recruit 4 patients per month to reach anticipated enrollment of 60. Data presented here is the number participants enrolled.

    Time frame: up to 90 days

Other outcomes

  1. Organ Dysfunction (Liver - Lille Score)

    Changes in liver-related function will be determined through assessment of Lille score. The model is based on: Age, Albumin, Bilirubin (initial), Bilirubin (day 7), Creatinine, PT. Survival probability at 6 months is defined by a cutoff of 0.45: 6-month survival probability of patients with a Lille model above 0.45 is about 25% contrary to patients with a Lille model below this cutoff (85% survival).

    Time frame: Up to 28 days

  2. Organ Dysfunction (Liver) With Model for End-stage Liver Disease (MELD)

    Changes in liver-related function will be determined through assessment of Model for End-stage Liver Disease (MELD) score, a number that ranges from 6 (least sick) to 40 (most sick) based on blood tests. The lab tests used to determine the MELD score are creatinine, bilirubin, sodium and international normalized ratio (INR).

    Time frame: Up to 28 days

  3. Organ Dysfunction (Liver Enzyme: Bilirubin)

    Changes in liver-related function will be determined through assessment of the liver enzyme bilirubin

    Time frame: Up to 28 days

  4. Organ Dysfunction (Liver Enzyme: Alkaline Phosphatase [ALP])

    Changes in liver-related function will be determined through assessment of liver enzymes (alkaline phosphatase \[ALP\])

    Time frame: Up to 28 days

  5. Organ Dysfunction (Liver Enzyme: Aspartate Aminotransferase [AST])

    Changes in liver-related function will be determined through assessment of liver enzymes (aspartate aminotransferase \[AST\])

    Time frame: Up to 28 days

  6. Organ Dysfunction (Liver Enzyme: Alanine Aminotransferase [ALT])

    Changes in liver-related function will be determined through assessment of liver enzymes (alanine aminotransferase \[ALT\])

    Time frame: Up to 28 days

  7. Organ Dysfunction (Multi-Organ) With Sequential Organ Failure Assessment (SOFA)

    Dysfunction in other organs will be assessed using Sequential Organ Failure Assessment (SOFA) score which is calculated based on a person's liver function, kidney function, nervous system, coagulation, circulation, and respiratory status. The score ranges from 0 (least sick) to 24 (most sick).

    Time frame: Up to 28 days

  8. Organ Dysfunction (Multi-Organ) With the Multi-Organ Dysfunction Score (MODS)

    Dysfunction in other organs will be assessed using Multi-organ dysfunction score (MODS), calculated based on a person's liver function, kidney function, nervous system, coagulation, circulation, and respiratory status. The score ranges from 0 (least sick) to 24 (most sick).

    Time frame: Up to 28 days

  9. Development of New or Recurrent Renal Failure.

    Creatinine rise ≥ 0.5 mg/dL or ≥ 20% from baseline or requiring renal replacement therapy.

    Time frame: Up to 28 days

  10. Racial and Ethnic Diversity in Subject Recruitment and Retention.

    Race and ethnicity of enrolled subjects and subjects who completed the study will be summarized using count and proportion to assess the study's objective of enrolling and retaining at least 10% Black and at least 10% Hispanic participants to study completion (90-days follow-up)follow-up.

    Time frame: Up to 90 days

07

Results

Posted Sep 29, 2026

Participant flow

Participant flow — Overall Study
MilestoneArm A: DigoxinArm B: No Digoxin
Started1310
Completed87
Not completed53

Outcome measures

PrimaryChange in Biomarkers of Inflammation

Change in IL-6, IL-10 and TNF-alpha levels (pg/ml) at day 3 in participants with acute alcohol associated hepatitis treated with digoxin vs no digoxin.

Time frame:
Day 3
Reported as:
Least squares mean · pg/ml
Change in Biomarkers of Inflammation
pg/mlArm A: DigoxinArm B: No Digoxin
IL-6-255.75 ± 44.6647.16 ± 38.40
IL-1019.71 ± 4.28-7.42 ± 3.74
TNF-alpha-146.13 ± 25.4326.83 ± 21.88
Statistical analysis
  • Arm A: Digoxin vs Arm B: No Digoxin · Mixed Models Analysis · p = 0.0148 · Mean difference (net): -302.92
  • Arm A: Digoxin vs Arm B: No Digoxin · Mixed Models Analysis · p = 0.0207 · Mean difference (net): 27.12
  • Arm A: Digoxin vs Arm B: No Digoxin · Mixed Models Analysis · p = 0.0147 · Mean difference (net): -172.95
SecondaryPracticality of Daily Digoxin Measurements

Practicality of daily digoxin measurements is recorded at the participant level as the proportion of timepoints where serum digoxin levels are checked within the pre-specified time window. It is summarized and reported as the mean and standard deviation of the proportion of eligible timepoints.

Time frame:
From Day 2 to Day 28 or until discharge, whichever sooner
Reported as:
Mean · Proportion of timepoints
Practicality of Daily Digoxin Measurements
Proportion of timepointsArm A: DigoxinArm B: No Digoxin
Practicality of Daily Digoxin Measurements1 ± 0—
SecondaryFeasibility of Digoxin Dosing in a Timely Manner.

Feasibility of digoxin dosing is recorded at the participant level as the proportion of eligible timepoints where the scheduled digoxin dose was given. It is summarized and reported as the mean and standard deviation of the proportion of scheduled timepoints.

Time frame:
From Day 1 to Day 28 or until discharge, whichever sooner
Reported as:
Mean · Proportion of timepoints
Feasibility of Digoxin Dosing in a Timely Manner.
Proportion of timepointsArm A: DigoxinArm B: No Digoxin
Feasibility of Digoxin Dosing in a Timely Manner.0.92 ± 0.18—
SecondaryFeasibility of Digoxin Dose Adjustments in Renal Insufficiency.

Feasibility of digoxin dose adjustments in renal insufficiency is recorded at the participant level as the proportion of timepoints where necessary dose adjustments were made appropriately in response to digoxin levels. Renal insufficiency was defined as a creatinine rise ≥ 0.3 mg/dL over 48 hours or ≥ 20% from baseline or requiring renal replacement therapy. It is reported as the mean and standard deviation of the proportion of timepoints.

Time frame:
From Day 0 to Day 28 or until discharge, whichever sooner
Reported as:
Mean · Proportion of timepoints
Feasibility of Digoxin Dose Adjustments in Renal Insufficiency.
Proportion of timepointsArm A: DigoxinArm B: No Digoxin
Feasibility of Digoxin Dose Adjustments in Renal Insufficiency.1 ± 0—
SecondaryMortality at 7, 14, 28, 90 Days. All Cause Mortality of Patients Enrolled in the Trial.

The mortality rates at different time points

Time frame:
Day 7, Day 14, Day 28, and Day 90
Reported as:
Count of participants · Participants
Mortality at 7, 14, 28, 90 Days. All Cause Mortality of Patients Enrolled in the Trial.
ParticipantsArm A: DigoxinArm B: No Digoxin
Day 710
Day 1410
Day 2810
Day 9012
Statistical analysis
  • Arm A: Digoxin vs Arm B: No Digoxin · Fisher Exact · p = 0.5596 · Odds ratio (or): 0.35Estimation Parameter performed for the day 90 timepoint.
SecondaryDevelopment of Arrhythmia

It refers to any type of arrhythmia which represents a change from baseline. It is reported as the proportion of individuals who developed an arrhythmia.

Time frame:
From Day 0 to Day 28 or until discharge, whichever sooner
Reported as:
Count of participants · Participants
Development of Arrhythmia
ParticipantsArm A: DigoxinArm B: No Digoxin
Development of Arrhythmia21
Statistical analysis
  • Arm A: Digoxin vs Arm B: No Digoxin · Fisher Exact · p = 1 · Odds ratio (or): 1.6
SecondaryRecruitment

Ability to recruit 4 patients per month to reach anticipated enrollment of 60. Data presented here is the number participants enrolled.

Time frame:
up to 90 days
Reported as:
Count of participants · Participants
Recruitment
ParticipantsArm A: DigoxinArm B: No Digoxin
Recruitment1310
Other pre-specifiedOrgan Dysfunction (Liver - Lille Score)

Changes in liver-related function will be determined through assessment of Lille score. The model is based on: Age, Albumin, Bilirubin (initial), Bilirubin (day 7), Creatinine, PT. Survival probability at 6 months is defined by a cutoff of 0.45: 6-month survival probability of patients with a Lille model above 0.45 is about 25% contrary to patients with a Lille model below this cutoff (85% survival).

Time frame:
Up to 28 days

Results for this outcome have not been posted.

Other pre-specifiedOrgan Dysfunction (Liver) With Model for End-stage Liver Disease (MELD)

Changes in liver-related function will be determined through assessment of Model for End-stage Liver Disease (MELD) score, a number that ranges from 6 (least sick) to 40 (most sick) based on blood tests. The lab tests used to determine the MELD score are creatinine, bilirubin, sodium and international normalized ratio (INR).

Time frame:
Up to 28 days

Results for this outcome have not been posted.

Other pre-specifiedOrgan Dysfunction (Liver Enzyme: Bilirubin)

Changes in liver-related function will be determined through assessment of the liver enzyme bilirubin

Time frame:
Up to 28 days

Results for this outcome have not been posted.

Other pre-specifiedOrgan Dysfunction (Liver Enzyme: Alkaline Phosphatase [ALP])

Changes in liver-related function will be determined through assessment of liver enzymes (alkaline phosphatase \[ALP\])

Time frame:
Up to 28 days

Results for this outcome have not been posted.

Other pre-specifiedOrgan Dysfunction (Liver Enzyme: Aspartate Aminotransferase [AST])

Changes in liver-related function will be determined through assessment of liver enzymes (aspartate aminotransferase \[AST\])

Time frame:
Up to 28 days

Results for this outcome have not been posted.

Other pre-specifiedOrgan Dysfunction (Liver Enzyme: Alanine Aminotransferase [ALT])

Changes in liver-related function will be determined through assessment of liver enzymes (alanine aminotransferase \[ALT\])

Time frame:
Up to 28 days

Results for this outcome have not been posted.

Other pre-specifiedOrgan Dysfunction (Multi-Organ) With Sequential Organ Failure Assessment (SOFA)

Dysfunction in other organs will be assessed using Sequential Organ Failure Assessment (SOFA) score which is calculated based on a person's liver function, kidney function, nervous system, coagulation, circulation, and respiratory status. The score ranges from 0 (least sick) to 24 (most sick).

Time frame:
Up to 28 days

Results for this outcome have not been posted.

Other pre-specifiedOrgan Dysfunction (Multi-Organ) With the Multi-Organ Dysfunction Score (MODS)

Dysfunction in other organs will be assessed using Multi-organ dysfunction score (MODS), calculated based on a person's liver function, kidney function, nervous system, coagulation, circulation, and respiratory status. The score ranges from 0 (least sick) to 24 (most sick).

Time frame:
Up to 28 days

Results for this outcome have not been posted.

Other pre-specifiedDevelopment of New or Recurrent Renal Failure.

Creatinine rise ≥ 0.5 mg/dL or ≥ 20% from baseline or requiring renal replacement therapy.

Time frame:
Up to 28 days

Results for this outcome have not been posted.

Other pre-specifiedRacial and Ethnic Diversity in Subject Recruitment and Retention.

Race and ethnicity of enrolled subjects and subjects who completed the study will be summarized using count and proportion to assess the study's objective of enrolling and retaining at least 10% Black and at least 10% Hispanic participants to study completion (90-days follow-up)follow-up.

Time frame:
Up to 90 days

Results for this outcome have not been posted.

Adverse events

Collected over 90 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Digoxin1/13 (7.7%)1/13 (7.7%)8/13 (61.5%)
Arm B: No Digoxin2/10 (20%)4/10 (40%)8/10 (80%)
Most frequent serious events
Most frequent serious events
EventArm A: DigoxinArm B: No Digoxin
Liver failureHepatobiliary disorders0/131/10
Acute kidney injuryRenal and urinary disorders0/131/10
Hepatorenal syndromeRenal and urinary disorders0/131/10
HypotensionVascular disorders0/131/10
Confusion ParanoiaPsychiatric disorders0/131/10
Aspiration pneumoniaRespiratory, thoracic and mediastinal disorders1/130/10
Most frequent other events
Showing 10 of 37
Most frequent other events
EventArm A: DigoxinArm B: No Digoxin
Abdominal painGastrointestinal disorders2/132/10
Urinary tract infectionInfections and infestations0/132/10
Acute kidney injuryRenal and urinary disorders1/132/10
DiarrheaGastrointestinal disorders0/131/10
Liver failureGastrointestinal disorders0/131/10
VomitingGastrointestinal disorders0/131/10
FatigueGeneral disorders0/131/10
BacteremiaInfections and infestations0/131/10
Upper respiratory infectionInfections and infestations1/131/10
FallInjury, poisoning and procedural complications0/131/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm A: DigoxinArm B: No DigoxinTotal
Mean46 ± 1146 ± 746 ± 9
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: DigoxinArm B: No DigoxinTotal
Female4610
Male9413
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: DigoxinArm B: No DigoxinTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American011
White9817
More than one race000
Unknown or Not Reported415
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: DigoxinArm B: No DigoxinTotal
Hispanic or Latino404
Not Hispanic or Latino91019
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Arm A: DigoxinArm B: No DigoxinTotal
United States131023
Model for End-Stage Liver Disease (MELD) score
Model for End-Stage Liver Disease (MELD) score(score on a scale)Arm A: DigoxinArm B: No DigoxinTotal
Mean26.7 ± 2.926.4 ± 3.426.6 ± 3.0
Maddrey's Discriminant Fraction (MDF) score
Maddrey's Discriminant Fraction (MDF) score(score on a scale)Arm A: DigoxinArm B: No DigoxinTotal
Mean57 ± 1854 ± 1955 ± 18
Mean concentration Alanine aminotransferase, units/liter (U/L)
Mean concentration Alanine aminotransferase, units/liter (U/L)(U/L)Arm A: DigoxinArm B: No DigoxinTotal
Mean50 ± 2857 ± 2453 ± 26

6 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Yale New Haven Hospital, Yale School of Medicine
    New Haven, Connecticut 06510, United States
09

References and documents

Publications

  • Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White RI Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978 Aug;75(2):193-9. PubMed 352788 ↗
  • Sahlman P, Nissinen M, Pukkala E, Farkkila M. Incidence, survival and cause-specific mortality in alcoholic liver disease: a population-based cohort study. Scand J Gastroenterol. 2016 Aug;51(8):961-6. doi: 10.3109/00365521.2016.1157889. Epub 2016 May 16. PubMed 27181618 ↗
  • Thursz MR, Richardson P, Allison M, Austin A, Bowers M, Day CP, Downs N, Gleeson D, MacGilchrist A, Grant A, Hood S, Masson S, McCune A, Mellor J, O'Grady J, Patch D, Ratcliffe I, Roderick P, Stanton L, Vergis N, Wright M, Ryder S, Forrest EH; STOPAH Trial. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015 Apr 23;372(17):1619-28. doi: 10.1056/NEJMoa1412278. PubMed 25901427 ↗
  • Scalese MJ, Salvatore DJ. Role of Digoxin in Atrial Fibrillation. J Pharm Pract. 2017 Aug;30(4):434-440. doi: 10.1177/0897190016642361. Epub 2016 Apr 10. PubMed 27067743 ↗
  • Ouyang X, Han SN, Zhang JY, Dioletis E, Nemeth BT, Pacher P, Feng D, Bataller R, Cabezas J, Starkel P, Caballeria J, Pongratz RL, Cai SY, Schnabl B, Hoque R, Chen Y, Yang WH, Garcia-Martinez I, Wang FS, Gao B, Torok NJ, Kibbey RG, Mehal WZ. Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1alpha Transactivation in Steatohepatitis. Cell Metab. 2018 Feb 6;27(2):339-350.e3. doi: 10.1016/j.cmet.2018.01.007. PubMed 29414684 ↗
  • Arteel GE, Iimuro Y, Yin M, Raleigh JA, Thurman RG. Chronic enteral ethanol treatment causes hypoxia in rat liver tissue in vivo. Hepatology. 1997 Apr;25(4):920-6. doi: 10.1002/hep.510250422. PubMed 9096598 ↗
  • Lee YS, Kim JW, Osborne O, Oh DY, Sasik R, Schenk S, Chen A, Chung H, Murphy A, Watkins SM, Quehenberger O, Johnson RS, Olefsky JM. Increased adipocyte O2 consumption triggers HIF-1alpha, causing inflammation and insulin resistance in obesity. Cell. 2014 Jun 5;157(6):1339-1352. doi: 10.1016/j.cell.2014.05.012. PubMed 24906151 ↗
  • Nath B, Levin I, Csak T, Petrasek J, Mueller C, Kodys K, Catalano D, Mandrekar P, Szabo G. Hepatocyte-specific hypoxia-inducible factor-1alpha is a determinant of lipid accumulation and liver injury in alcohol-induced steatosis in mice. Hepatology. 2011 May;53(5):1526-37. doi: 10.1002/hep.24256. PubMed 21520168 ↗
  • Palmer BF, Clegg DJ. Ascent to altitude as a weight loss method: the good and bad of hypoxia inducible factor activation. Obesity (Silver Spring). 2014 Feb;22(2):311-7. doi: 10.1002/oby.20499. Epub 2013 Oct 15. PubMed 23625659 ↗
  • Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012 Feb 3;148(3):399-408. doi: 10.1016/j.cell.2012.01.021. PubMed 22304911 ↗
  • Hollman A. Drugs for atrial fibrillation. Digoxin comes from Digitalis lanata. BMJ. 1996 Apr 6;312(7035):912. doi: 10.1136/bmj.312.7035.912. No abstract available. PubMed 8611904 ↗
  • Digoxin FDA insert. . [cited 2021 3/15/2021]
  • (CDC)., C.f.D.C.a.P. Alcohol and Public Health: Alcohol-Related Disease Impact (ARDI). Annual Average for United States 2011-2015 Alcohol-Attributable Deaths Due to Excessive Alcohol Use, All Ages. [cited 2021 3/20/2021]
  • (NIH)., N.I.o.H. Alcohol Facts and Statistics. [cited 2021 3/20/2021]
  • Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003 Feb 19;289(7):871-8. doi: 10.1001/jama.289.7.871. PubMed 12588271 ↗
  • Ouyang AJ, Lv YN, Zhong HL, Wen JH, Wei XH, Peng HW, Zhou J, Liu LL. Meta-analysis of digoxin use and risk of mortality in patients with atrial fibrillation. Am J Cardiol. 2015 Apr 1;115(7):901-6. doi: 10.1016/j.amjcard.2015.01.013. Epub 2015 Jan 14. PubMed 25660972 ↗
  • Dasgupta A. Endogenous and exogenous digoxin-like immunoreactive substances: impact on therapeutic drug monitoring of digoxin. Am J Clin Pathol. 2002 Jul;118(1):132-40. doi: 10.1309/3VNP-TWFQ-HT9A-1QH8. PubMed 12109847 ↗
  • Yang SS, Hughes RD, Williams R. Digoxin-like immunoreactive substances in severe acute liver disease due to viral hepatitis and paracetamol overdose. Hepatology. 1988 Jan-Feb;8(1):93-7. doi: 10.1002/hep.1840080119. PubMed 2828215 ↗
  • Rosenkranz B, Frolich JC. Falsely elevated digoxin concentrations in patients with liver disease. Ther Drug Monit. 1985;7(2):202-6. doi: 10.1097/00007691-198506000-00011. PubMed 4024214 ↗
  • Nikou GC, Vyssoulis GP, Venetikou MS, Karga HI, Karoutsos KA, Toutouzas PK. Digoxin-like substance(s) interfere(s) with serum estimations of the drug in cirrhotic patients. J Clin Gastroenterol. 1989 Aug;11(4):430-3. doi: 10.1097/00004836-198908000-00016. PubMed 2547866 ↗
  • Digoxin conversion calculator.
  • O'Shea RS, Dasarathy S, McCullough AJ; Practice Guideline Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology. 2010 Jan;51(1):307-28. doi: 10.1002/hep.23258. No abstract available. PubMed 20034030 ↗
  • Bode C, Bode JC. Effect of alcohol consumption on the gut. Best Pract Res Clin Gastroenterol. 2003 Aug;17(4):575-92. doi: 10.1016/s1521-6918(03)00034-9. PubMed 12828956 ↗
  • Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcohol associated Hepatitis (AlcHepNet). [cited 2021 03/29]
  • R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing 2020

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Jun 2025, 44 months.

Results were first posted in Sep 2026, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2021
First posted
Aug 20, 2021
StartActual
Oct 8, 2021
Primary completionActual
Jun 22, 2025
CompletionActual
Sep 12, 2025
Results first posted
Sep 29, 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Sep 29, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange in biomarkersBiomarkers of inflammationInflammationTime frame: day 3 → Day 3
Sep 29, 2026
Documents
Secondary outcomes
15 edited, 1 description edited
What changed in the outcomes
  • EditedPracticality of daily digoxin measurementsDaily Digoxin MeasurementsTime frame: Up to 28 days → From Day 2 to Day 28 or until discharge, whichever sooner
  • EditedFeasibility of digoxin dosingDigoxin Dosing in a timely mannerTimely Manner.Time frame: Up to 28 days → From Day 1 to Day 28 or until discharge, whichever sooner
  • EditedFeasibility of digoxin dose adjustmentsDigoxin Dose Adjustments in renal insufficiencyRenal Insufficiency.Time frame: Up to 28 days → From Day 0 to Day 28 or until discharge, whichever sooner
  • EditedMortality at 7, 14, 28, 90 daysDays. All cause mortalityCause Mortality of patients enrolledPatients Enrolled in the trialTrial.Time frame: Up to 90 days → Day 7, Day 14, Day 28, and Day 90
  • EditedDevelopment of ECG abnormalitiesArrhythmiaTime frame: Up to 28 days → From Day 0 to Day 28 or until discharge, whichever sooner
  • DescriptionRecruitment: how it is measured was reworded
  • Editedother outcomeOrgan dysfunctionDysfunction (Liver - Lille Score)Time frame: Up to 28 days
  • Editedother outcomeOrgan dysfunctionDysfunction (Liver) withWith Model for End-stage Liver Disease (MELD)Time frame: Up to 28 days
  • Editedother outcomeOrgan dysfunctionDysfunction (Liver Enzyme: Bilirubin)Time frame: Up to 28 days
  • Editedother outcomeOrgan dysfunctionDysfunction (Liver Enzyme: Alkaline Phosphatase [ALP])Time frame: Up to 28 days
  • Editedother outcomeOrgan dysfunctionDysfunction (Liver Enzyme: Aspartate Aminotransferase [AST])Time frame: Up to 28 days
  • Editedother outcomeOrgan dysfunctionDysfunction (Liver Enzyme: Alanine Aminotransferase [ALT])Time frame: Up to 28 days
  • Editedother outcomeOrgan Dysfunction (Multi-Organ) withWith Sequential Organ Failure Assessment (SOFA)Time frame: Up to 28 days
  • Editedother outcomeOrgan Dysfunction (Multi-Organ) withWith the Multi-Organ Dysfunction Score (MODS)Time frame: Up to 28 days
  • Editedother outcomeDevelopment of newNew or recurrent renal failureRecurrent Renal Failure.Time frame: Up to 28 days
  • Editedother outcomeRacial and ethnic diversityEthnic Diversity in subject recruitmentSubject Recruitment and retentionRetention.Time frame: Up to 90 days
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange in biomarkersBiomarkers of inflammationInflammationTime frame: day 3 → Day 3
    Secondary outcomes 15 edited, 1 description edited
    What changed in the outcomes
    • EditedPracticality of daily digoxin measurementsDaily Digoxin MeasurementsTime frame: Up to 28 days → From Day 2 to Day 28 or until discharge, whichever sooner
    • EditedFeasibility of digoxin dosingDigoxin Dosing in a timely mannerTimely Manner.Time frame: Up to 28 days → From Day 1 to Day 28 or until discharge, whichever sooner
    • EditedFeasibility of digoxin dose adjustmentsDigoxin Dose Adjustments in renal insufficiencyRenal Insufficiency.Time frame: Up to 28 days → From Day 0 to Day 28 or until discharge, whichever sooner
    • EditedMortality at 7, 14, 28, 90 daysDays. All cause mortalityCause Mortality of patients enrolledPatients Enrolled in the trialTrial.Time frame: Up to 90 days → Day 7, Day 14, Day 28, and Day 90
    • EditedDevelopment of ECG abnormalitiesArrhythmiaTime frame: Up to 28 days → From Day 0 to Day 28 or until discharge, whichever sooner
    • DescriptionRecruitment: how it is measured was reworded
    • Editedother outcomeOrgan dysfunctionDysfunction (Liver - Lille Score)Time frame: Up to 28 days
    • Editedother outcomeOrgan dysfunctionDysfunction (Liver) withWith Model for End-stage Liver Disease (MELD)Time frame: Up to 28 days
    • Editedother outcomeOrgan dysfunctionDysfunction (Liver Enzyme: Bilirubin)Time frame: Up to 28 days
    • Editedother outcomeOrgan dysfunctionDysfunction (Liver Enzyme: Alkaline Phosphatase [ALP])Time frame: Up to 28 days
    • Editedother outcomeOrgan dysfunctionDysfunction (Liver Enzyme: Aspartate Aminotransferase [AST])Time frame: Up to 28 days
    • Editedother outcomeOrgan dysfunctionDysfunction (Liver Enzyme: Alanine Aminotransferase [ALT])Time frame: Up to 28 days
    • Editedother outcomeOrgan Dysfunction (Multi-Organ) withWith Sequential Organ Failure Assessment (SOFA)Time frame: Up to 28 days
    • Editedother outcomeOrgan Dysfunction (Multi-Organ) withWith the Multi-Organ Dysfunction Score (MODS)Time frame: Up to 28 days
    • Editedother outcomeDevelopment of newNew or recurrent renal failureRecurrent Renal Failure.Time frame: Up to 28 days
    • Editedother outcomeRacial and ethnic diversityEthnic Diversity in subject recruitmentSubject Recruitment and retentionRetention.Time frame: Up to 90 days
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05014087
Lead sponsor
Yale University
Responsible party
Bubu Banini, MD, PhD (Assistant Professor of Internal Medicine, Yale University) — Principal investigator
First posted
Aug 20, 2021
Start date
Oct 8, 2021
Primary completion
Jun 22, 2025
Completion
Sep 12, 2025
Results posted
Sep 29, 2026
Last update
Sep 29, 2026

Study contacts

Bubu Banini, MD, PhD
principal investigator · Yale University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Digoxin

Start the discussion